Trials / Completed
CompletedNCT02229825
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
An Eight-week, Randomized, Double-blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 mg Per Day in Patients Hospitalized for Severe Depression
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 339 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to assess efficacy of Duloxetine 120 mg and Duloxetine 60 mg in patients hospitalized for severe depression after 4 weeks of treatment. To evaluate the rescue option in non-responding patients. Safety of Duloxetine will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duloxetine | Capsule |
| DRUG | Placebo | Capsule |
Timeline
- Start date
- 2007-02-09
- Primary completion
- 2008-08-26
- Completion
- 2008-08-26
- First posted
- 2014-09-01
- Last updated
- 2023-10-23
- Results posted
- 2023-10-23
Source: ClinicalTrials.gov record NCT02229825. Inclusion in this directory is not an endorsement.